Clinical Study
Antirelapse Efficacy of Various Primaquine Regimens for Plasmodium vivax
Table 2
Differentiation of recurrences as relapse or reinfection.
| | PQ regimens | Group A
(no PQ) | Group B
(15 mg/day × 14 days) | Group C
(30 mg/day × 7 days) | Group D
(30 mg/day × 14 days) |
| | Number of patients who completed 6 months of followup | 305 | 322 | 298 | 317 | | Number of patients showing recurrence (%)* | 50 (16.39) | 26 (8.07) | 30 (10.07) | 21 (6.62) |
| | As per the month of recurrence | | Number of relapses | 21 | 5 | 12 | 9 | | Number of reinfections | 29 | 21 | 18 | 12 | | Relapse rate** | 6.89% | 1.55% | 4.00% | 2.84% | | Reinfection rate | 9.51% | 6.52% | 6.00% | 3.79% |
| | Genotyping (PCR-RFLP) | | Paired primary and recurrence samples available for analysis | 24 | 15 | 18 | 16 | | Number of PCR-RFLP genotyping results available for the paired samples | 16 | 11 | 11 | 9 | | Number of samples showing same genotypes | 8 | 3 | 5 | 5 | | Number of samples showing different genotypes | 8 | 8 | 6 | 4 | | Relapse rate*** | 8.20% | 2% | 4.58% | 3.68% | | Reinfection rate | 8.20% | 5.82% | 5.49% | 2.9% |
| | Genotyping (PCR sequencing) | | Paired primary and recurrence samples available and analyzed | 24 | 15 | 18 | 16 | | Number of PCR sequencing results available for the paired samples | 12 | 11 | 13 | 13 | | Number of samples showing same genotypes | 2 | 2 | 2 | 3 | | Number of samples showing different genotypes | 10 | 9 | 11 | 10 | | Relapse rate | 2.73% | 1.47% | 1.55% | 1.53% | | Reinfection rate | 13.66% | 6.60% | 8.52% | 5.09% |
|
|
, , .
|
